FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206653075> ?p ?o ?g. }

• W3206653075 abstract "The aim of this study was to evaluate diagnostic means, host factors, delay of occurrence, and outcome of patients with COVID-19 pneumonia and fungal coinfections in the intensive care unit (ICU). From 1 February to 31 May 2020, we anonymously recorded COVID-19-associated pulmonary aspergillosis (CAPA), fungemia (CA-fungemia), and pneumocystosis (CA-PCP) from 36 centers, including results on fungal biomarkers in respiratory specimens and serum. We collected data from 154 episodes of CAPA, 81 of CA-fungemia, 17 of CA-PCP, and 5 of other mold infections from 244 patients (male/female [M/F] ratio = 3.5; mean age, 64.7 ± 10.8 years). CA-PCP occurred first after ICU admission (median, 1 day; interquartile range [IQR], 0 to 3 days), followed by CAPA (9 days; IQR, 5 to 13 days), and then CA-fungemia (16 days; IQR, 12 to 23 days) (P < 10-4). For CAPA, the presence of several mycological criteria was associated with death (P < 10-4). Serum galactomannan was rarely positive (<20%). The mortality rates were 76.7% (23/30) in patients with host factors for invasive fungal disease, 45.2% (14/31) in those with a preexisting pulmonary condition, and 36.6% (34/93) in the remaining patients (P = 0.001). Antimold treatment did not alter prognosis (P = 0.370). Candida albicans was responsible for 59.3% of CA-fungemias, with a global mortality of 45.7%. For CA-PCP, 58.8% of the episodes occurred in patients with known host factors of PCP, and the mortality rate was 29.5%. CAPA may be in part hospital acquired and could benefit from antifungal prescription at the first positive biomarker result. CA-fungemia appeared linked to ICU stay without COVID-19 specificity, while CA-PCP may not really be a concern in the ICU. Improved diagnostic strategy for fungal markers in ICU patients with COVID-19 should support these hypotheses. IMPORTANCE To diagnose fungal coinfections in patients with COVID-19 in the intensive care unit, it is necessary to implement the correct treatment and to prevent them if possible. For COVID-19-associated pulmonary aspergillosis (CAPA), respiratory specimens remain the best approach since serum biomarkers are rarely positive. Timing of occurrence suggests that CAPA could be hospital acquired. The associated mortality varies from 36.6% to 76.7% when no host factors or host factors of invasive fungal diseases are present, respectively. Fungemias occurred after 2 weeks in ICUs and are associated with a mortality rate of 45.7%. Candida albicans is the first yeast species recovered, with no specificity linked to COVID-19. Pneumocystosis was mainly found in patients with known immunodepression. The diagnosis occurred at the entry in ICUs and not afterwards, suggesting that if Pneumocystis jirovecii plays a role, it is upstream of the hospitalization in the ICU." @default.
• W3206653075 created "2021-10-25" @default.
• W3206653075 creator A5005152545 @default.
• W3206653075 creator A5007829509 @default.
• W3206653075 creator A5011581053 @default.
• W3206653075 creator A5015993923 @default.
• W3206653075 creator A5020040419 @default.
• W3206653075 creator A5023504070 @default.
• W3206653075 creator A5025894766 @default.
• W3206653075 creator A5027753891 @default.
• W3206653075 creator A5028438452 @default.
• W3206653075 creator A5031801644 @default.
• W3206653075 creator A5035371903 @default.
• W3206653075 creator A5036767449 @default.
• W3206653075 creator A5037358300 @default.
• W3206653075 creator A5039185549 @default.
• W3206653075 creator A5039278700 @default.
• W3206653075 creator A5040983615 @default.
• W3206653075 creator A5043601609 @default.
• W3206653075 creator A5044822714 @default.
• W3206653075 creator A5050695114 @default.
• W3206653075 creator A5057460351 @default.
• W3206653075 creator A5058570354 @default.
• W3206653075 creator A5059831856 @default.
• W3206653075 creator A5060084930 @default.
• W3206653075 creator A5061702594 @default.
• W3206653075 creator A5062436503 @default.
• W3206653075 creator A5063798888 @default.
• W3206653075 creator A5064423853 @default.
• W3206653075 creator A5070331214 @default.
• W3206653075 creator A5073240872 @default.
• W3206653075 creator A5073507191 @default.
• W3206653075 creator A5075168686 @default.
• W3206653075 creator A5087264141 @default.
• W3206653075 creator A5087485138 @default.
• W3206653075 creator A5089277410 @default.
• W3206653075 creator A5090698087 @default.
• W3206653075 date "2021-10-31" @default.
• W3206653075 modified "2023-10-16" @default.
• W3206653075 title "COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave" @default.
• W3206653075 cites W1819112229 @default.
• W3206653075 cites W1970856277 @default.
• W3206653075 cites W2084203711 @default.
• W3206653075 cites W2107600719 @default.
• W3206653075 cites W2123114992 @default.
• W3206653075 cites W2167423543 @default.
• W3206653075 cites W2170452931 @default.
• W3206653075 cites W2384346244 @default.
• W3206653075 cites W2588571452 @default.
• W3206653075 cites W2617272400 @default.
• W3206653075 cites W2653464886 @default.
• W3206653075 cites W2886381549 @default.
• W3206653075 cites W2917995335 @default.
• W3206653075 cites W2980017741 @default.
• W3206653075 cites W2992250822 @default.
• W3206653075 cites W3010278110 @default.
• W3206653075 cites W3019320147 @default.
• W3206653075 cites W3019336217 @default.
• W3206653075 cites W3021335315 @default.
• W3206653075 cites W3027918021 @default.
• W3206653075 cites W3031985609 @default.
• W3206653075 cites W3036050467 @default.
• W3206653075 cites W3036766665 @default.
• W3206653075 cites W3038867861 @default.
• W3206653075 cites W3039484850 @default.
• W3206653075 cites W3044228167 @default.
• W3206653075 cites W3045013692 @default.
• W3206653075 cites W3046139360 @default.
• W3206653075 cites W3081313246 @default.
• W3206653075 cites W3091803574 @default.
• W3206653075 cites W3092528479 @default.
• W3206653075 cites W3096002794 @default.
• W3206653075 cites W3111905732 @default.
• W3206653075 cites W3112534727 @default.
• W3206653075 cites W3112984291 @default.
• W3206653075 cites W3129262340 @default.
• W3206653075 cites W3135588806 @default.
• W3206653075 cites W3136681803 @default.
• W3206653075 cites W3156797019 @default.
• W3206653075 cites W3159154946 @default.
• W3206653075 cites W3165615511 @default.
• W3206653075 cites W3167271178 @default.
• W3206653075 cites W3176054457 @default.
• W3206653075 cites W3176509544 @default.
• W3206653075 cites W3176728552 @default.
• W3206653075 cites W4210642183 @default.
• W3206653075 doi "https://doi.org/10.1128/spectrum.01138-21" @default.
• W3206653075 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8528108" @default.
• W3206653075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34668768" @default.
• W3206653075 hasPublicationYear "2021" @default.
• W3206653075 type Work @default.
• W3206653075 sameAs 3206653075 @default.
• W3206653075 citedByCount "30" @default.
• W3206653075 countsByYear W32066530752022 @default.
• W3206653075 countsByYear W32066530752023 @default.
• W3206653075 crossrefType "journal-article" @default.
• W3206653075 hasAuthorship W3206653075A5005152545 @default.
• W3206653075 hasAuthorship W3206653075A5007829509 @default.
• W3206653075 hasAuthorship W3206653075A5011581053 @default.
• W3206653075 hasAuthorship W3206653075A5015993923 @default.

• next